Eurifel RCP FeLV
vaccine against feline viral rhinotracheitis, calicivirosis, panleucopenia and leukaemia in cats
Table of contents
Overview
The marketing authorisation for Eurifel RCP FeLV has not been renewed by the marketing authorisation holder and is now withdrawn.
Authorisation details
| Product details | |
|---|---|
| Name |
Eurifel RCP FeLV
|
| Agency product number |
EMEA/V/C/000067
|
| Active substance |
|
| International non-proprietary name (INN) or common name |
vaccine against feline viral rhinotracheitis, calicivirosis, panleucopenia and leukaemia in cats
|
| Species |
Cats
|
| Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI06AH
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Merial
|
| Revision |
8
|
| Date of issue of marketing authorisation valid throughout the European Union |
08/03/2002
|
| Contact address |
29, avenue Tony Garnier
69007 Lyon FRANCE |
Product information
23/07/2004 Eurifel RCP FeLV - EMEA/V/C/000067 -
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Immunologicals for felidae
Therapeutic indication
Vaccine against feline viral rhinotracheitis, feline calicivirosis, feline panleucopenia and feline leukaemia.
Stimulates active immunity against feline rhinotracheitis virus, feline calicivirus, feline panleucopenia virus and feline leukaemia virus.
The feline leukaemia vaccine strain is a recombinant canarypox virus expressing the env and gag genes of FeLV-A. Under field conditions, only sub-group A is infective and immunisation against subgroup A provides full protection against A, B and C. After inoculation, the virus expresses the protective proteins, but does not replicate in the cat. As a consequence, the vaccine induces an immune status against feline leukaemia virus.